Home   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  >  
EGFR

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

EGFR

Chemical Structure Cat. No. Product Name CAS No.
TAK-788 Chemical Structure
BCP31045 TAK-788 AP32788
TAK-788 is a small, oral inhibitor of EGFR [epidermal growth factor receptor] and HER2 [human epidermal growth factor receptor 2].
Avitinib maleate Chemical Structure
BCP19161 Avitinib maleate 1822357-78-7
Avitinib maleate, the maleate salt form of avitinib, is a pyrrolopyrimidine-based, irreversible epidermal growth factor receptor (EGFR) mutant-selective inhibitor(IC50= 7.68 nM), with potential antineoplastic activity.
Chrysophanic acid Chemical Structure
BCP23439 Chrysophanic acid 481-74-3
Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.
Tesevatinib Chemical Structure
BCP23438 Tesevatinib 781613-23-8
XL-647 (Tesevatinib, EXEL-7647, KD-019) is a novel spectrum-selective kinase inhibitor that potently inhibits the EGFR, ErbB2, KDR and EphB4 with IC50 of 0.3, 16, 1.5 and 1.4 nM, respectively.
ZD-4190 Chemical Structure
BCP30854 ZD-4190 413599-62-9
ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
LUT-014 Chemical Structure
BCP30636 LUT-014 2274819-46-2
LUT014 is a topical B-Raf Inhibitor, a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects
Necitumumab Chemical Structure
BCP30497 Necitumumab 906805-06-9
Necitumumab is a recombinant human IgG1 monoclonal antibody used as an antineoplastic.
TAS6417 Chemical Structure
BCP30474 TAS6417 1661854-97-2
TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM.
Lazertinib Chemical Structure
BCP30440 Lazertinib 1903008-80-9
Lazertinib is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.
AST2818 mesylate Chemical Structure
BCP30340 AST2818 mesylate 2130958-55-1
AST2818 mesylate is an EGFR inhibitor.
123下一页末页共 108 条记录 1 / 11 页 
0086-13720134139